RxDoctor Payments Data

Robert Moskowitz, DO

Vascular Surgery · Albuquerque, NMNPI 1093022402

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,631 of the $6,958 with a category attached, or 80.9%. 22 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 30.7% of the total. Reporting peaked in 2019 at $2,569 and has fallen 74.3% since, to $660 in 2025.

$6,958in general payments, 2019–2025

Across 129 payments — averaging $53.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$2K
  • Abbott$1K
  • Medtronic$1K
  • Tactile Systems Technology Inc$296
  • Endologix LLC$295
  • Bard Peripheral Vascular, Inc.$255
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1,16317%
  • Food & beverage$5,63181%
  • Education$1652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,958 in reported general payments places this provider in the 70th percentile of 21 vascular surgery providers in New Mexico.

See all vascular surgery providers in New Mexico

Medicare billing

Part B allowed, 2024
$158,754
Medicare patients
2,014
Services billed
3,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cilostazol47$1,431
ClopidogrelClopidogrel Bisulfate47$769
Atorvastatin Calcium33$646

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →